Revised SPC: Oramorph (morphine) Oral Solution

SPC states decreased exposure to oral P2Y12 inhibitor in acute coronary syndrome may occur with concomitant use, likely due to reduced GI motility. If concomitant use cannot be avoided, and fast P2Y12 inhibition crucial, use of a parenteral P2Y12 inhibitor may be considered.

Source:

electronic Medicines compendium